CEO Bancel acquires 160,314 shares for $5,004,318.13 as MRNA stock down 81.8% from 52-week high
On 2025-03-03, CEO Stephane Bancel purchased 160,314 shares across 2 transactions at a blended average price of $31.22, increasing his holdings to 9.21M shares. The timing is notable: the stock is currently trading at $30.37, down 81.8% from its 52-week high of $166.61 and down 23.0% over the past 30 days. Fundamentally, the company faces headwinds—annual revenue growth was -52.8%, and it remains unprofitable on a full-year basis despite recent quarterly revenue of $1.9B. Bancel's prior trade history at MRNA shows 4 of 5 prior sells were well-timed at the 90-day mark, suggesting he has demonstrated ability to read this specific stock. This purchase occurs in a sharply depressed price environment relative to recent highs, warranting close tracking of whether this represents confidence in a recovery or a miscalculation against continued deterioration.